Skip to main content
Terug
PTKFF logo

PT Kalbe Farma Tbk.

Datakwaliteit: 100%
Oversold
PTKFF
OTC Healthcare Drug Manufacturers - General
€ 0,06
▼ € 0,01 (-17,44%)
Marktkapitalisatie: 2,67B
Dagbereik
€ 0,06 € 0,06
52-Weeksbereik
€ 0,06 € 0,10
Volume
1.680
50D / 200D Gem.
€ 0,07 / € 0,08
Vorige Slotkoers
€ 0,06

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,0 0,4
P/B 0,0 2,9
ROE % 14,7 3,8
Net Margin % 9,9 3,9
Rev Growth 5Y % 9,0 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 9,00% annually over 5 years — modest growth
Earnings grew 17,13% over the past year
ROE of 14,66% — decent returns on equity
Debt/Equity of 0,02 — conservative balance sheet
Generating 3,53T in free cash flow
Cash machine — converts 109,08% of earnings into free cash flow

Groei

Revenue Growth (5Y)
9,00%
Revenue (1Y)7,16%
Earnings (1Y)17,13%
FCF Growth (3Y)10,42%

Kwaliteit

Return on Equity
14,66%
ROIC13,07%
Net Margin9,93%
Op. Margin12,47%

Veiligheid

Debt / Equity
0,02
Current Ratio4,11
Interest Coverage72,22

Waardering

P/E Ratio
0,00
P/B Ratio0,00
EV/EBITDA-1,02
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7,16% Revenue Growth (3Y) 6,19%
Earnings Growth (1Y) 17,13% Earnings Growth (3Y) -2,12%
Revenue Growth (5Y) 9,00% Earnings Growth (5Y) 4,35%
Profitability
Revenue (TTM) 32,63T Net Income (TTM) 3,24T
ROE 14,66% ROA 11,01%
Gross Margin 39,71% Operating Margin 12,47%
Net Margin 9,93% Free Cash Flow (TTM) 3,53T
ROIC 13,07% FCF Growth (3Y) 10,42%
Safety
Debt / Equity 0,02 Current Ratio 4,11
Interest Coverage 72,22 Dividend Yield 0,02%
Valuation
P/E Ratio 0,00 P/B Ratio 0,00
P/S Ratio 0,00 PEG Ratio 1,25
EV/EBITDA -1,02 Dividend Yield 0,02%
Market Cap 2,67B Enterprise Value -4,16T

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 32,63T 30,45T 28,93T 26,26T 23,11T
Net Income 3,24T 2,77T 3,38T 3,18T 2,73T
EPS (Diluted) 70,22 59,81 72,71 67,92 58,31
Gross Profit 12,96T 11,55T 11,70T 11,28T 10,25T
Operating Income 4,07T 3,63T 4,49T 4,16T 3,64T

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 29,43T 27,06T 27,24T 25,67T 22,56T
Total Liabilities 4,84T 3,94T 5,14T 4,40T 4,29T
Shareholders' Equity 22,79T 21,42T 20,39T 19,58T 17,41T
Total Debt 559,22B 618,54B 1,17T 626,16B 1,16T
Cash & Equivalents 4,72T 3,23T 3,95T 6,22T 5,21T
Current Assets 17,19T 15,92T 16,71T 15,71T 13,08T
Current Liabilities 4,19T 3,24T 4,43T 3,53T 3,18T

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#449 of 1024
47
Custom Deep Value Investing (Seth Klarman)
#506 of 820
36
Value Defensive Investing (Benjamin Graham)
#662 of 708
3

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026